EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Wojciech Jurczak iD, Michal Kwiatek, Jaroslaw Czyz iD, Ederson Roberto de Mattos, Ki-Seong Eom iD, Alexander Egle iD, Anna Panovska iD, Zhanet Grudeva Popova iD, Hsuan-Jen Shih iD, Luis Felipe Casado Montero iD, Paolo Sportoletti iD, Vu Minh Hua und 9 weitere

Journal of Clinical Oncology · 20.02.2026 · 44 (6) · 466-475

DOI: 10.1200/jco-25-02380 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2026. Verfasst von Wojciech Jurczak und 20 weiteren Autor:innen. Beteiligte Einrichtung: National Research Institute of Oncology, Krakow, Poland. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols, Rituximab. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). METHODS Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)–assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)–assessed PFS, safety, and tolerability. RESULTS Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367]; P < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)–related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively. CONCLUSION Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bendamustine HydrochlorideLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsRituximabPyrimidinesHumansMaleFemaleAgedMiddle AgedAged, 80 and overAdultProgression-Free SurvivalProtein Kinase InhibitorsAdeninePyrazoles

Substanzen

Bendamustine HydrochlorideRituximabPyrimidinesProtein Kinase InhibitorsAdeninepirtobrutinibPyrazoles

Autor:innen und Institutionen

  • National Research Institute of Oncology, Krakow, Poland.
  • AIDPORT Clinical Trials Hospital, Skorzewo, Poland.
  • Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland.
  • Hematology Department, Hospital Amaral Carvalho, Jau, Brazil.
  • Catholic Hematology Hospital, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
  • Third Medical Department for Hematology, Oncology, Hemostaseology, Infectious Disease and Rheumatology, Paracelsus University Hospital, Salzburg, Austria.

ORCID-Profile: Wojciech Jurczak, Jaroslaw Czyz, Ki-Seong Eom, Alexander Egle, Anna Panovska, Zhanet Grudeva Popova, Hsuan-Jen Shih, Luis Felipe Casado Montero, Paolo Sportoletti, Shinsuke Iida, Katherine Bao, Tomasz Wrobel

Zitieren

APA

Jurczak, W., Kwiatek, M., Czyz, J., Roberto de Mattos, E., Eom, K. S., Egle, A., Panovska, A., Popova, Z. G., Shih, H. J., Casado Montero, L. F., Sportoletti, P., Hua, V. M., D'Olimpio, J. T., Iida, S., Ito, R., Bao, K., Fink, A., Su, W., Ruppert, A. S., …, & Wrobel, T. (2026). BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Clinical Oncology, 44(6), 466-475. https://doi.org/10.1200/jco-25-02380

Vancouver

Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, et al. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Clinical Oncology. 2026;44(6):466-475. doi:10.1200/jco-25-02380

BibTeX
@article{Jurczak2026,
  author = {Jurczak, Wojciech and Kwiatek, Michal and Czyz, Jaroslaw and Roberto de Mattos, Ederson and Eom, Ki-Seong and Egle, Alexander and Panovska, Anna and Popova, Zhanet Grudeva and Shih, Hsuan-Jen and Casado Montero, Luis Felipe and Sportoletti, Paolo and Hua, Vu Minh and D'Olimpio, James T and Iida, Shinsuke and Ito, Rodrigo and Bao, Katherine and Fink, Anne and Su, Weiji and Ruppert, Amy S and Levy, Alejandro and Wrobel, Tomasz},
  title = {BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {6},
  pages = {466--475},
  doi = {10.1200/jco-25-02380}
}
Kostenlos starten →